NFE2L3 and cancer: Therefore, we hypothesize that NFE2L3, a novel biomarker in malignant pleural mesothelioma, may promote the differentiation of Th2 cells through the IL-2/STAT5/NLRP3 signaling pathway in multiple cancers.